Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
AstraZeneca plans to invest about $285 million in a biological medicines manufacturing facility in Södertälje, Sweden. The plant, which will focus on filling and packaging protein therapeutics, will initially supply medicines for clinical trial programs for AstraZeneca and MedImmune, the drug company’s biologics R&D arm. The project could create between 150 and 200 jobs, according to the company, which already operates a tablet and capsule manufacturing site in Södertälje. AstraZeneca’s announcement closely follows Alexion Pharmaceuticals’ decision to build a $505 million biologics plant near Dublin, Ireland.
This article has been sent to the following recipient: